CAS 90357-06-5|Bicalutamide

Introduction：Basic information about CAS 90357-06-5|Bicalutamide, including its chemical name, molecular formula, synonyms, physicochemical properties, and safety information, etc.

Table of Contents

1. Names
2. Bicalutamide BiologicalActivity
3. Chemical & Physical Properties
4. Toxicological Information
CHEMICAL IDENTIFICATION
HEALTH HAZARD DATA
ACUTE TOXICITY DATA
5. Safety Information
6. Customs
7. Articles89
8. Synonyms

Common Name	Bicalutamide
CAS Number	90357-06-5	Molecular Weight	430.373
Density	1.5±0.1 g/cm3	Boiling Point	650.3±55.0 °C at 760 mmHg
Molecular Formula	C₁₈H₁₄F₄N₂O₄S	Melting Point	191-193°C
MSDS	ChineseUSA	Flash Point	347.1±31.5 °C
Symbol	GHS07	Signal Word	Warning

Names

Name	bicalutamide
Synonym	More Synonyms

Bicalutamide BiologicalActivity

Description	Bicalutamide is a non-steroidal androgen receptor inhibitor.
Related Catalog	Signaling Pathways >>Others >>Androgen ReceptorSignaling Pathways >>Autophagy >>AutophagyResearch Areas >>Cancer
References	[1]. Nicola J. Clegg,1 John Wongvipat,1,2 Jim Joseph, ARN-509: a novel anti-androgen for prostate cancer treatment. Cancer Res. 2012 March 15; 72(6): 1494-1503. [2]. RACHEL M. SQUILLACE, DAVID MILLER, SCOTT D. WARDWELL, Synergistic activity of the mTOR inhibitor ridaforolimus and the antiandrogen bicalutamide in prostate cancer models. Int J Oncol. 2012 August; 41(2): 425-432. [3]. Nakabayashi M, Werner L, Courtney KD, Phase II trial of RAD001 and bicalutamide for castration-resistant prostate cancer. BJU Int. 2012 Dec;110(11):1729-35.

Description

Bicalutamide is a non-steroidal androgen receptor inhibitor.

Related Catalog

Signaling Pathways >>Others >>Androgen ReceptorSignaling Pathways >>Autophagy >>AutophagyResearch Areas >>Cancer

References

[1]. Nicola J. Clegg,1 John Wongvipat,1,2 Jim Joseph, ARN-509: a novel anti-androgen for prostate cancer treatment. Cancer Res. 2012 March 15; 72(6): 1494-1503.

[2]. RACHEL M. SQUILLACE, DAVID MILLER, SCOTT D. WARDWELL, Synergistic activity of the mTOR inhibitor ridaforolimus and the antiandrogen bicalutamide in prostate cancer models. Int J Oncol. 2012 August; 41(2): 425-432.

[3]. Nakabayashi M, Werner L, Courtney KD, Phase II trial of RAD001 and bicalutamide for castration-resistant prostate cancer. BJU Int. 2012 Dec;110(11):1729-35.

Chemical & Physical Properties

Density	1.5±0.1 g/cm3
Boiling Point	650.3±55.0 °C at 760 mmHg
Melting Point	191-193°C
Molecular Formula	C₁₈H₁₄F₄N₂O₄S
Molecular Weight	430.373
Flash Point	347.1±31.5 °C
Exact Mass	430.061035
PSA	115.64000
LogP	4.94
Vapour Pressure	0.0±2.0 mmHg at 25°C
Index of Refraction	1.578
InChIKey	LKJPYSCBVHEWIU-UHFFFAOYSA-N
SMILES	CC(O)(CS(=O)(=O)c1ccc(F)cc1)C(=O)Nc1ccc(C#N)c(C(F)(F)F)c1
Storage condition	Store at RT

Toxicological Information

CHEMICAL IDENTIFICATION

RTECS NUMBER :: TX1413500

CHEMICAL NAME :: Propanamide, N-(4-cyano-3-(trifluoromethyl)phenyl)-3-((4-fluorophe nyl)sulfonyl)-2-hydro xy-2- methyl-, (+-)-

CAS REGISTRY NUMBER :: 90357-06-5

LAST UPDATED :: 199712

DATA ITEMS CITED :: 5

MOLECULAR FORMULA :: C18-H14-F4-N2-O4-S

MOLECULAR WEIGHT :: 430.40

HEALTH HAZARD DATA

ACUTE TOXICITY DATA

TYPE OF TEST :: LD - Lethal dose

ROUTE OF EXPOSURE :: Oral

SPECIES OBSERVED :: Rodent - rat

DOSE/DURATION :: >2 gm/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

REFERENCE :: JTSCDR Journal of Toxicological Sciences. (Japanese Soc. of Toxicological Sciences, 4th Floor, Gakkai Center Bldg., 4-16, Yayoi 2-chome, Bunkyo-ku, Tokyo 113, Japan) V.1- 1976- Volume(issue)/page/year: 22,75,1997

TYPE OF TEST :: LD - Lethal dose

ROUTE OF EXPOSURE :: Oral

SPECIES OBSERVED :: Rodent - mouse

DOSE/DURATION :: >2 gm/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

REFERENCE :: JTSCDR Journal of Toxicological Sciences. (Japanese Soc. of Toxicological Sciences, 4th Floor, Gakkai Center Bldg., 4-16, Yayoi 2-chome, Bunkyo-ku, Tokyo 113, Japan) V.1- 1976- Volume(issue)/page/year: 22,75,1997

TYPE OF TEST :: LD - Lethal dose

ROUTE OF EXPOSURE :: Oral

SPECIES OBSERVED :: Mammal - dog

DOSE/DURATION :: >2 gm/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

REFERENCE :: JTSCDR Journal of Toxicological Sciences. (Japanese Soc. of Toxicological Sciences, 4th Floor, Gakkai Center Bldg., 4-16, Yayoi 2-chome, Bunkyo-ku, Tokyo 113, Japan) V.1- 1976- Volume(issue)/page/year: 22,75,1997 ** REPRODUCTIVE DATA **

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Subcutaneous

DOSE :: 420 mg/kg

SEX/DURATION :: female 21 day(s) pre-mating

TOXIC EFFECTS :: Reproductive - Paternal Effects - other effects on male Endocrine - changes in luteinizing hormone

REFERENCE :: ACENA7 Acta Endocrinologica (Copenhagen). (Periodica, Skolegade 12 E, DK-2500 Valby, Denmark) V.1- 1948- Volume(issue)/page/year: 125,547,1991

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Subcutaneous

DOSE :: 420 mg/kg

SEX/DURATION :: female 21 day(s) pre-mating

TOXIC EFFECTS :: Reproductive - Paternal Effects - spermatogenesis (incl. genetic material, sperm morphology, motility, and count) Reproductive - Paternal Effects - testes, epididymis, sperm duct Reproductive - Paternal Effects - prostate, seminal vesicle, Cowper's gland, accessory glands

REFERENCE :: ACENA7 Acta Endocrinologica (Copenhagen). (Periodica, Skolegade 12 E, DK-2500 Valby, Denmark) V.1- 1948- Volume(issue)/page/year: 125,547,1991

Safety Information

Symbol	GHS07
Signal Word	Warning
Hazard Statements	H315-H319-H335
Precautionary Statements	P261-P305 + P351 + P338
Personal Protective Equipment	dust mask type N95 (US);Eyeshields;Gloves
Hazard Codes	Xi: Irritant;
Risk Phrases	R36/37/38
Safety Phrases	26-36
RIDADR	3077
RTECS	TX1413500
Packaging Group	III
Hazard Class	9
HS Code	2929909090

Customs

HS Code	2929909090
Summary	2929909090 other compounds with other nitrogen function VAT:17.0% Tax rebate rate:9.0% Supervision conditions:none MFN tariff:6.5% General tariff:30.0%

Articles89

CYP3A5 regulates prostate cancer cell growth by facilitating nuclear translocation of AR.

Prostate 75(5) , 527-38, (2015)

The central role of androgen receptor (AR) signaling is established in prostate cancer growth and progression. We propose CYP3A5 is part of a feedback loop that modulates the sensitivity of AR to andr...

Differential androgen deprivation therapies with anti-androgens casodex/bicalutamide or MDV3100/Enzalutamide versus anti-androgen receptor ASC-J9(R) Lead to promotion versus suppression of prostate cancer metastasis.

J. Biol. Chem. 288(27) , 19359-69, (2013)

Despite the fact that androgen deprivation therapy (ADT) can effectively reduce prostate cancer (PCa) size, its effect on PCa metastasis remains unclear. We examined the existing data on PCa patients ...

TLR3 engagement induces IRF-3-dependent apoptosis in androgen-sensitive prostate cancer cells and inhibits tumour growth in vivo.

J. Cell. Mol. Med. 19(2) , 327-39, (2015)

Toll-like receptors (TLRs) are a family of highly conserved transmembrane proteins expressed in epithelial and immune cells that recognize pathogen associated molecular patterns. Besides their role in...

Synonyms

(2R)-N-[4-Cyano-3-(trifluoromethyl)phenyl]-3-[(4-fluorophenyl)sulfonyl]-2-hydroxy-2-methylpropanamide

Propanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]-3-[(4-fluorophenyl)sulfonyl]-2-hydroxy-2-methyl-, (2R)-

Bicaiutamide

(1E,2R)-N-[4-Cyano-3-(trifluoromethyl)phenyl]-3-[(4-fluorophenyl)sulfonyl]-2-hydroxy-2-methylpropanimidic acid

Propanimidic acid, N-[4-cyano-3-(trifluoromethyl)phenyl]-3-[(4-fluorophenyl)sulfonyl]-2-hydroxy-2-methyl-, (1E,2R)-

25mg

ODEX

BicalutaMide API

MFCD00869971

R-bicalutamide

Bicalutamide

R-Bicalutimide

Cosudex

Recommended......